Self-reported Antiretroviral Therapy in Injection Drug Users

作者: David D Celentano , David Vlahov , Sylvia Cohn , Vera M Shadle , Olugbenga Obasanjo

DOI: 10.1001/JAMA.280.6.544

关键词:

摘要: Context.—The US Public Health Service and the International AIDS Society–USA recently published recommendations for antiretroviral therapy (ART) persons infected with human immunodeficiency virus (HIV); however, anecdotal evidence suggests that HIV-infected injection drug users (IDUs) may not be receiving optimal care as defined by recommendations.Objective.—To assess ART use in IDUs.Design.—A cross-sectional survey of self-reported between July 1996 and June 1997 IDUs.Setting.—A community-based clinic affiliated Johns Hopkins University, Baltimore, Md.Participants.—A total 404 IDUs CD4+ cell counts less than 0.50×109/L recruited into a longitudinal study 1988 and 1989.Main Outcome Measure.—Self-reported was assessed: no current therapy, monotherapy, or combination or without protease inhibitor.Results.—One half (199/404 [49%]) patients reported recent ART. A total of 14% (58/404) had monotherapy, 23% (90/404) were receiving therapy without inhibitor, (57/404) triple-combination therapy with inhibitor. multivariate analysis factors associated with ART showed continuity HIV-related outpatient visit (odds ratio [OR], 4.30; 95% confidence interval [CI], 2.36-7.81 OR, 2.84; 95% CI, 1.66-4.88, respectively), count less than 0.20×109 (OR, 2.41; CI, 1.51-3.84), being drug treatment 2.16; 1.34-3.47; 2.12; 1.23-3.66, respectively), and unemployment 2.31; 1.21-4.40) reporting ART use. In other analysis, likely to receive inhibitors were current injectors 0.5; 0.3-1.0) those recently incarcerated (OR, 0.2; 0.03-0.9), but acquired syndrome were more 2.0; 0.9-4.6). Protease inhibitor doubled (P<.01) from July and December 1996 January (7.7% 14.8%, respectively).Conclusions.—Those infected HIV who tended be active clinical disease have contact health care providers. Although we do information on judgment regarding treatment decisions whether persons prescribed taken, the proportion subjects reporting suggests strategies for improving treatment this population are indicated. Expanding simultaneous treatment services infection substance abuse would enhance the response these related epidemics.

参考文章(14)
Robert C. Freeman, Gloria M. Rodriguez, John F. French, Compliance with AZT treatment regimen of HIV-seropositive injection drug users: A neglected issue. Aids Education and Prevention. ,vol. 8, pp. 58- 71 ,(1996)
David Bangsberg, Jacqueline P Tulsky, Frederick M Hecht, Andrew R Moss, Protease Inhibitors in the Homeless JAMA: The Journal of the American Medical Association. ,vol. 278, pp. 63- 65 ,(1997) , 10.1001/JAMA.1997.03550010077044
Supriya Mehta, Richard D. Moore, Neil M.H. Graham, Potential factors affecting adherence with HIV therapy AIDS. ,vol. 11, pp. 1665- 1670 ,(1997) , 10.1097/00002030-199714000-00002
V. De Gruttola, T. Fleming, D. Y. Lin, R. Coombs, Perspective: Validating Surrogate Markers—Are We Being Naive? The Journal of Infectious Diseases. ,vol. 175, pp. 237- 246 ,(1997) , 10.1093/INFDIS/175.2.237
Stanislav V. Kasl, Issues in patient adherence to health care regimens. Journal of human stress. ,vol. 1, pp. 5- 48 ,(1975) , 10.1080/0097840X.1975.9939542
A. Steiner, W. Vetter, A. F. Schaub, Compliance to treatment. Clinical and Experimental Hypertension. ,vol. 15, pp. 1121- 1130 ,(1993) , 10.3109/10641969309037099
Joyce A. Cramer, Compliance Declines Between Clinic Visits Archives of Internal Medicine. ,vol. 150, pp. 1509- 1510 ,(1990) , 10.1001/ARCHINTE.1990.00390190143023
Richard D. Moore, David Stanton, Ramana Gopalan, Richard E. Chaisson, Racial Differences in the Use of Drug Therapy for HIV Disease in an Urban Community The New England Journal of Medicine. ,vol. 330, pp. 763- 768 ,(1994) , 10.1056/NEJM199403173301107
Anthony D Kelleher, Monika Roggensack, Angel B Jaramillo, Don E Smith, Alan Walker, Irene Gow, Marilyn McMurchie, Jan Harris, Gary Patou, David A Cooper, Community HIV Research Network Investigators, Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects AIDS. ,vol. 12, pp. 175- 182 ,(1998) , 10.1097/00002030-199802000-00007